Artemisinin derivatives like dihydroartemisinin (DHA) upregulate IFN-γ expression within the tumor microenvironment while enhancing CD8+ T-cell expansion [327]., potentially resensitizing tumors that have developed resistance to PD-1/PD-L1 blockade [328]. Here, CD8A is linked to neoplasm.